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ABSTRACT
Objectives: Describe the incidence, prevalence and
survival of patients needing renal replacement therapy
(RRT) for end-stage renal disease (ESRD) due to
diabetes mellitus (DM)-related glomerulosclerosis or
nephropathy (diabetic nephropathy, DN) in the
Netherlands.
Design: Using the national registry for RRT (RENINE-
registry), data of all Dutch individuals initiating RRT for
ESRD and having DN as primary diagnosis in the
period 2000–2012 were obtained.
Setting: Observational study in the Netherlands.
Patients: Patients with ESRD needing RRT for DN.
Outcome measurements: Age and gender adjusted
incidence and prevalence of RRT for DN in the period
2000–2012. In addition, trends in time and patient’s
survival were examined.
Results: The prevalence of DM in the general
population increased from approximately 466 000 in
2000 to 815 000 in 2011. The number of individuals
who started RRT with DN as primary diagnosis was
17.4 per million population (pmp) in 2000 and
19.1 pmp in 2012, with an annual percentage change
(APC) of 0.8% (95% CI −0.4 to 2.0). For RRT due to
type 1 DN, the incidence decreased from 7.3 to
3.5 pmp (APC −4.8%, 95% CI −6.5 to −3.1) while it
increased for type 2 DN from 10.1 to 15.6 pmp (APC
3.1%, 95% CI 1.3 to 4.8). After 2009, the prevalence
of RRT for DN remained stable (APC 1.0%, 95% CI
−0.4 to 2.5). Compared to the period 2000–2004,
patients initiating RRT and dialysis in 2005–2009 had
better survival, HRs 0.8 (95% CI 0.7 to 0.8) and 0.8
(95% CI 0.7 to 0.9), respectively, while survival after
kidney transplantation remained stable, HR 0.8, 95% CI
0.5 to 1.1).
Conclusions: Over the last decade, the incidence of
RRT for DN was stable, with a decrease in RRT due to
type 1 DN and an increase due to type 2 DN, while
survival increased.
INTRODUCTION
Diabetic nephropathy (DN) is considered to
be the main cause of end-stage renal disease
(ESRD) in many countries, with an ever
increasing incidence and prevalence.1 2 In
general, its frequency as cause of ESRD has
bypassed all other causes and ESRD due to
DN is seen as one of the main reasons for
the accelerating growth in patients with
ESRD, thus contributing not only to an
important loss of quality of life and early
death but also to a vast increase in health
expenditure worldwide.3 4
In the USA, for instance, the incidence of
ESRD due to DN was 156 per million popula-
tion (pmp) in 2011.4 Recently, a report from
France found an incidence of 56 pmp while
this number was 27.6 pmp in the UK.5 6
Although the incidence of renal replacement
therapy (RRT) due to DN seemed to
increase in most countries, in line with the
increasing incidence of diabetes mellitus
(DM) among the population, other countries
reported a stabilisation or even a decrease.5–9
The aim of the present study was to report
any recent changes in the incidence and
prevalence of RRT for DN in the
Netherlands, taking into account the
increased prevalence of DM in the general
population from approximately 260 000 in
1993, 466 000 in 2000 to 815 000 in
2011.10 11 Furthermore, we analysed the
Strengths and limitations of this study
▪ This study reports the incidence, prevalence and
survival of patients needing renal replacement
therapy (RRT) for end-stage renal disease
(ESRD) due to diabetic nephropathy (DN).
▪ Nationwide data from 2000 to 2012 for DN due
to both type 1 and type 2 diabetes mellitus are
reported.
▪ It cannot be ruled out that some of the patients
with unknown or missing primary causes of RRT
actually had RRT for ESRD due to DN.
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survival rates on RRT for ESRD due to DN between the
periods 2000–2004 and 2005–2009.
METHODS
Study design and aims
This nationwide cohort study is the third ‘Dutch dia-
betes estimates’ (DUDE) study. The DUDE studies aim
to investigate the magnitude and impact of DM and its
complications in the Netherlands. Aim of the present
study was to investigate the course of the incidence and
prevalence of RRT for ESRD due to DN in the
Netherlands in the period 2000–2012. Furthermore, sur-
vival among patients on RRT for ESRD due to DN in
this period was analysed.
Data collection
Data from the RENINE registry were used. All Dutch
centres (n=69) providing RRT collaborated and shared
their individual patient’s data with the RENINE registry
on a continuous basis, yielding a nationwide and 100%
registration of treated patients.12
In the Dutch RENINE registry, information including
primary renal disease necessitating RRT is registered
according to the coding of the European Renal
Association European Dialysis and Transplant Association
(ERA-EDTA) registry. In this registry, DM as primary
renal disease is registered under the EDTA codes 80
(Diabetes glomerulosclerosis or diabetic nephropathy—
Type 1 diabetes mellitus) and 81 (Diabetes glomerulo-
sclerosis or diabetic nephropathy—Type 2 diabetes
mellitus).13 14 In this manuscript, patients with either
code 80 or code 81 as primary cause of ESRD necessitat-
ing RRTwill be further referenced as patients with type 1
or type 2 DN (T1DN or T2DN, respectively).
In the RENINE registry, RRT is deﬁned as dialysis
(peritoneal or haemodialysis) or kidney (also including
kidney-pancreas Tx) transplantation (Tx). Patients are
only registered in the RENINE registry if they are using
RRT for >30 days. The incidence of RRT was deﬁned as
the number of new patients per year and prevalence was
deﬁned as the number of patients alive and on RRT on
31 December of the relevant year. Both crude and the
age and gender adjusted incidence, using the European
Union (27 countries) age and gender distribution, were
calculated. For both of these items, the mid-year popula-
tion (30 June) was used as denominator. Owing to
unknown or missing data regarding the cause of ESRD
in some centres, additional sensitivity analyses were per-
formed for the crude incidence in order to compare
outcomes between centres with <20% missing (n=38)
and ≥20% (n=31) missing data.
Statistical analysis
Trends in time were analysed with Joinpoint regression.
The Joinpoint regression technique allows identiﬁcation
of points in time where a signiﬁcant change in the
linear slope of a trend occurs. The analysis starts with
zero joinpoints (ie, a straight line) and then tests
whether one or more joinpoints are signiﬁcantly differ-
ent and must be added to the model.15 The slope of a
trend was calculated using the observed rate as the
outcome variable and the year as the explanatory vari-
able. The analysis was adjusted for changes in the age
and gender distribution of the population. The annual
percentage change (APC) was subsequently computed
by the formula APC=[exp(β)−1]×100, where β denotes
the regression coefﬁcient representing the estimated
effect of time on the rate. A negative APC describes a
decreasing trend and a positive APC describes an
increasing trend. Joinpoint regression software (V.3.3)
provided by the Surveillance Research Programme of
the US National Cancer Institute was used to examine
whether trends were linear.
Statistical analysis of unadjusted and adjusted survival,
for patients starting RRT between 2000 and 2009, was
performed by Cox proportional hazards regression. For
the analysis of patient survival on dialysis the ﬁrst day on
dialysis was the starting point, the event studied was
death and reasons for censoring were recovery of renal
function, loss to follow-up, end-of-follow-up time and
kidney transplantation. For the analysis of patient and
graft survival after transplantation, the date of the ﬁrst
transplant was deﬁned as the ﬁrst day of follow-up. For
the analysis of patient survival after transplantation,
death was the event studied and for graft survival the
events were graft failure and death. Reasons for censor-
ing were loss-to-follow-up and end-of-follow-up period.
SAS V.9.1 software was used for all statistical analyses.
RESULTS
Crude incidence and prevalence
In 2012, the total Dutch population consisted of
16 730 348 persons.16 Of all 2011 persons (120.2 pmp)
starting RRT in the year 2012, 328 (19.6 pmp) needed
RRT for ESRD due to DN. Over time, the crude inci-
dence increased from 15.6 pmp in 2000 to 19.6 pmp in
2012, increasing by 1.9% annually.
The crude prevalence of patients using RRT for all
causes in the year 2012 was 15 449 (923.4 pmp) of which
1817 (108.6 pmp) used RRT for ESRD due to DN. Over
time, the crude prevalence increased at a slower rate: by
6.7% annually from 2000 to 2009 and by 2.6% annually
from 2009 to 2012.
The crude incidence and prevalence of RRT for DN,
both T1DN and T2DN, non-DN and unknown/missing
causes of ESRD are presented in online supplementary
appendix 1.
Adjusted incidence
The age and gender adjusted incidence of RRT for
ESRD due to non-DN causes increased from 2000 to
2008 by 2% annually and remained stable after 2008
(table 1). As for RRT in ESRD due to DN, the incidence
was stable over time, but trends were different by type of
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diabetes. There was an increase in incidence of RRT for
T2DN from 2000 to 2012 by 3.1% annually, while the
incidence of RRT for ESRD due to T1DN decreased in
this period by −4.8% annually.
Sensitivity analyses of the adjusted incidence in
centres with <20% and ≥20% missing or unknown
primary causes of ESRD also showed an increasing inci-
dence for T2DN and decreasing incidence for T1DN in
both groups. Among centres with <20% missing or
unknown primary causes of ESRD, there was an annual
increase of 2.1% in the incidence of RRT for ESRD due
to both forms of DN in the period 2000 to 2012;
however, it is stabilised in centres with ≥20% missing or
unknown primary causes of ESRD (see online supple-
mentary appendix 2A–D).
Adjusted prevalence
The age and gender adjusted prevalence of RRT for
ESRD due to non-DN causes increased from 2000 to
2009 by 2.6% annually and remained stable after 2009
(table 2). Prevalence of RRT for DN increased from
2000 to 2009 by 5.8% annually and remained stable
after 2009. For T2DN, prevalence increased at a declin-
ing rate: 12.4% in the period 2000 to 2003 and 8.7% in
the period 2003 to 2009, and remained stable after
2009. For T1DN, prevalence increased from 2000 to
2010 by 1.2% and stabilised from 2010 onwards.
Treatment modality
From 2000 to 2012, adjusted incidence of dialysis for DN
was stable due to an annual increase of 3.1% for T2DN
and a decrease of −6.1% for T1DN in this period (see
online supplementary appendix 3A). Incidence of Tx
for both forms of DN increased by 11.1% annually:
10.1% for T2 DN and 8.8% for T1DN. Prevalence of dia-
lysis for DN increased from 2000 to 2008 by 5.9% annu-
ally and remained stable afterwards. For T2DN,
prevalence of dialysis increased at a declining rate: from
2000 to 2003 by 12.5% annually to 7.2% in the period
2003 to 2009, and was stable after 2009. For T1DN, an
initial decrease of prevalence in the period 2000 to 2010
by −1.3% annually seemed to disappear after 2010.
Prevalence of patients with Tx increased from 2000 to
2004 by 4.6% annually and from 2004 to 2012 by 7.7%.
For T1DN there was an annual increase of 3.5%
throughout the follow-up period, while for T2DN preva-
lence only increased between 2002 and 2010 by 18.7%
annually (see online supplementary appendix 3B).
Survival
Survival and subsequent HRs were signiﬁcantly worse for
patients on RRT for ESRD due to DN compared to a
non-DN reference population (table 3). Compared to
patients with RRT for ESRD due to T2DN, patients with
T1DN had a worse survival on dialysis (both for haemo-
dialysis and peritoneal dialysis, see online supplementary
appendix 4A,B) but not after kidney transplantation
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(also for graft survival, see online supplementary appen-
dix 4C).
When comparing survival between patients who started
RRT for ESRD due to DN in the period 2000–2004 and
2005–2009, patients in the latter time frame had signiﬁ-
cantly better outcomes (adjusted HR 0.76, 95% CI 0.69 to
0.84). Their survival on dialysis was better (HR 0.77, 95%
CI 0.70 to 0.85) while there was a non-signiﬁcant trend
towards improvement in patient’s survival Tx (HR 0.77
95% CI 0.54 to 1.10). Both for T1DN and T2DN, survival
on RRT improved in the period 2005–2009 as compared
to 2000–2004: HR 0.75 (95% CI 0.62 to 0.90) and HR
0.77 (95% CI 0.69 to 0.87), respectively (see online sup-
plementary appendix 4).
DISCUSSION
We report a 4.8% average yearly decrease in age and
gender adjusted annual incidence of RRT for ESRD due
to T1DN and a 3.1% increase for T2DN in the period
2000 to 2012. The combined incidence of RRT for
ESRD due to both types of DN has been stable over the
period. Together with an increased survival over these
years, this may indicate that the number of patients
needing RRT for ESRD due to DN is stable and that
these patients now live longer while on RRT.
These ﬁndings are remarkable, given the current
increase in patients with T2DM in the Netherlands. Best
estimations for T2DM show an increase from approxi-
mately 260 000 in 1993, to 466 000 in 2000 and to
815 000 in 2011.10 11 Although trends cannot be extra-
polated one-on-one from observational data, we
hypothesise it may suggest that the presently advocated
approach with emphasis on early preventive measures
(including lifestyle advices, stricter control of blood pres-
sure and lipid proﬁle disturbances, and improved gly-
caemic regulation), increased use of renoprotective
medication (including ACE inhibitors or angiotensin II
receptor antagonists), improved accessibility to RRT
facilities or changes in healthcare delivery in the
Netherlands may have had a positive impact.10 17–20
Nevertheless, other explanations for our ﬁndings
should be discussed. First and foremost, centres with
unknown or missing data regarding the primary cause
of ESRD may have confounded our ﬁndings. Indeed,
sensitivity analyses showed different trends in the age
and gender adjusted incidence of RRT for ESRD due to
DN between centres with <20% and ≥20% missing data,
but the ones with fewer missing data conﬁrmed our
results. Second, a lag time in diagnosis of DN and devel-
opment of ESRD should be taken into account.
However, the transition rate from each stage of DN to
the next one, of approximately 2.5% per year, should
imply a higher prevalence of T2DN-related ESRD in the
present study and this is quickly increasing disease preva-
lence in the general population.21 Third, the results
could also indicate that, in line with other countries, in
recent years more often a non-dialytic, conservative
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treatment is chosen for patients with ESRD due to
DN.22 23 Finally, the dramatic scenario of increasing
mortality among patients with DM before initiating RRT
could be hypothesised. However, as the life expectancy
of Dutch patients with T2DM is reported to be stable, at
a level equal to the general population, this latter scen-
ario is not quite conceivable.20
In a previous Dutch report until 2002, the incidence
rates of RRT were also increasing for T2DN and decreas-
ing for T1DN.24 The current report extends the studied
period and adds to these observations by demonstrating
a stabilisation of ESRD due to DN. This is in accordance
with reports from other registries: Sørensen et al9
reported a stabilisation in Danish patients with DM who
were referred for RRT and recently a French study
showed that in the period 2007 to 2011, there was a
decreasing incidence of RRT for ESRD due to T1DN
and after an increase until 2009, a stabilisation for
T2DN.6 A report from the USA also showed a decreasing
incidence of ESRD treatment for DN.25
Nevertheless, notable differences in the rate and
course of the incidence of RRT for ESRD due to DN
between countries exist. In 2005, the mean annual
increase of the age and gender adjusted incidence of
RRT for T2DN in 10 European registries was estimated to
be 12%, with a variation of 7–21%.13 Worldwide, the rela-
tive incidence rate of ESRD due to diabetes was reported
as ranging from less than 20% in Russia and Norway to
60% in Singapore or Mexico.4 When comparing 2011
incidence data with other developed European countries
with an equal (∼7.5%) diabetes prevalence in the
general population and Japan and the USA (table 4), the
differences are still remarkable.4 26 Thus it seems that
these differences may not be solely explained by varia-
tions in diabetes prevalence in the general population
between countries. Finding explanations and subsequent
solutions for these differences might help to alleviate the
burden of ESRD due to DN.
Analysis of survival in the present study conﬁrms previ-
ous ﬁndings that mortality is higher among patients with
RRT for ESRD due to DN, in particular T1DN, com-
pared to patients with RRT for ESRD due to a non-DN
cause, implying an additional detrimental effect of dia-
betes induced end-organ damage.27 28 Regarding sur-
vival by modality, Schroijen et al reported almost the
same crude HR for mortality (1.51) for patients with
ESRD due to DN on dialysis in seven other European
countries.28 In accordance with previous reports, we
found that renal transplantation yielded higher
Table 3 Patient survival probabilities and crude HRs and age and gender adjusted HRs of patients starting RRT, subdivided
into RRT (both dialysis and Tx), dialysis and kidney transplantation in the period 2000–2010
Adjusted 1 year
survival (95% CI)
Adjusted 5 year
survival (95% CI)
Unadjusted 5 year
survival (95% CI)
Crude HR
(95% CI)
Adjusted
HR (95% CI)
Survival on RRT
No DN 90.2 (89.7 to 90.7) 62.1 (61.1 to 63.1) 53.6 (53.0 to 54.1) 1 (ref) 1 (ref)
DN both 88.1 (87.2 to 89.1) 49.7 (47.9 to 51.6) 39.3 (38.6 to 40.1) 1.50 (1.43 to 1.58) 1.45 (1.38 to 1.53)
T1DN 84.6 (82.2 to 87.0) 41.1 (37.7 to 44.8) 44.5 (43.0 to 45.9) 1.29 (1.18 to 1.40) 1.83 (1.68 to 2.00)
T2DN 89.2 (88.1 to 90.3) 52.6 (50.5 to 54.8) 37.1 (36.3 to 37.9) 1.61 (1.52 to 1.70) 1.35 (1.27 to 1.43)
Survival on dialysis
No DN 88.3 (87.7 to 88.9) 53.7 (52.5 to 55.0) 44.4 (43.9 to 44.9) 1 (ref) 1 (ref)
DN both 86.5 (85.4 to 87.7) 43.3 (41.3 to 45.4) 35.0 (34.3 to 35.7) 1.26 (1.19 to 1.33) 1.32 (1.25 to 1.39)
T1DN 83.2 (80.7 to 85.9) 33.8 (30.2 to 38.0) 35.0 (33.7 to 36.3) 1.28 (1.17 to 1.41) 1.72 (1.57 to 1.88)
T2DN 87.6 (86.3 to 88.8) 46.4 (44.1 to 48.8) 35.0 (34.2 to 35.8) 1.25 (1.18 to 1.32) 1.21 (1.14 to 1.29)
Survival after kidney Tx
No DN 97.5 (97.1 to 98.0) 90.8 (90.0 to 91.8) 87.4 (86.5 to 88.3) 1 (ref) 1 (ref)
DN both 94.4 (92.9 to 96.0) 83.2 (80.4 to 86.0) 74.6 (71.7 to 77.3) 2.07 (1.77 to 2.42) 1.85 (1.58 to 2.17)
T1DN 94.7 (92.5 to 97.0) 84.4 (80.7 to 88.4) 81.7 (77.8 to 85.0) 1.49 (1.20 to 1.86) 1.76 (1.41 to 2.20)
T2DN 94.2 (92.2 to 96.3) 82.1 (78.4 to 86.1) 65.2 (60.9 to 69.1) 3.09 (2.52 to 3.80) 1.94 (1.58 to 2.38)
Categories may not add up because of rounding off. Dialysis is defined as both peritoneal dialysis or haemodialysis. For survival probabilities
subdivided into haemodialysis and peritoneal dialysis please see online supplementary appendix 4. Data on graft survival is presented in
online supplementary appendix 4.
DN, diabetic nephropathy; RRT, renal replacement therapy; T1DN, type 1 DN; T2DN, type 2 DN; Tx, kidney transplantation.
Table 4 Incidence rates of ESRD due to DN: differences
between countries
Country
Diabetes
national
prevalence (%)
Incidence rate of
ESRD due to DN
(pmp)
Belgium 6.63 37.8
Denmark 7.51 29.7
France 7.30 32.4
Japan 11.2 131.3
The Netherlands 7.31 18.6
Norway 5.85 14.5
Spain 8.14 29.3
Sweden 5.71 29.7
USA 10.94 159.2
Based on 2011 data derived from refs 4 and 26.
DN, diabetic nephropathy; ESRD, end-stage renal disease; pmp,
per million population.
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(approximately a doubling) survival rates than dialysis.4
Although individual patient data is lacking, this may well
be due to the selection of healthier participants for
renal transplantation as compared to dialysis. It should
be noted that the survival rates among patients with DN
using RRT have increased during the last decade.
Although there could be different explanations for this
ﬁnding, that is, better control of (cardiovascular) risk
factors, improved dialysis techniques or a higher
number of renal transplantations, this important ﬁnding
adds to the aforementioned hypothesis that changes
within the present healthcare system and delivery also
contribute to improved care for patients with ESRD.
This study is subject to some limitations. As mentioned
before, it cannot be ruled out that some of the patients
with unknown/missing primary causes of RRT indeed
had DN. It should also be taken into account that the
classiﬁcation of diabetes as primary cause of ESRD into
T1DN and T2DN was made primarily by the attending
nephrologist. Furthermore, the diagnosis of DN was
made clinically and was rarely based on biopsy ﬁndings.
Although this may have induced errors in classiﬁcation,
it reﬂects clinical practice. Finally, as no (longitudinal)
individual patient data on health status was available we
can only hypothesise about the inﬂuence of healthcare
or patient-related characteristics on, for example, differ-
ences between patients with T1DN and T2DN. One pos-
sible hypothesis is that earlier identiﬁcation of T1DN
patients, with subsequent earlier surveillance for protein-
uria and an earlier start of renoprotective medications,
may explain observed differences between T1DN and
T2DN. Furthermore, patients with T1DN, most likely
being younger, are more often deemed suitable for Tx.
In conclusion, the incidence of RRT for ESRD due to
DN was stable in the Netherlands over the last decade
reﬂecting a decrease for T1DN and an increase for
T2DN. The overall incidence and prevalence are also
relatively low in comparison with most developed coun-
tries. Taken together with improved survival rates this
may suggest that changes in healthcare have been suc-
cessful with regard to the prevention and subsequent
treatment of ESRD due to DN.
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